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Abstract: Antimicrobial stewardship programs (ASPs) have been suggested to reduce antimicrobial
resistance phenomena in veterinary medicine, as antibiotics are commonly used without micro-
biological confirmation. The aim of the present study is to design a specific working flow for a
tailored antimicrobial treatment in the case of canine and feline urinary tract infections (UTIs). Urine
samples were collected by cystocentesis from 16 dogs and 12 cats presenting acute signs of UTI.
The therapy was decided according to the minimal inhibitory concentration, and it was possible
to monitor 14 dogs and 11 cats. Rescue therapy (amoxicillin and clavulanic acid) was included in
emergency cases. Escherichia coli, Proteus mirabilis, and Streptococcus canis were isolated in dogs, and
Escherichia coli, Staphylococcus pseudintermedius, and Staphylococcus aureus were isolated in cats. No
multidrug-resistant strains were detected, but all Staphylococci were methicillin resistant. Only one
cat received rescue therapy, and only one dog was recruited. Dogs were treated with tetracycline
(1/14), fluoroquinolones (6/14), beta-lactams (6/14), and gentamicin (1/14), while cats received
fluoroquinolones (3/11), nitrofurans (1/11), clindamycin (1/11), and beta-lactams (6/11). The success
rate was very high. Our findings are interesting because this is the first ASP in Italy, and it may be
used as a model to develop ASPs for other pathologies.
Keywords: antibiotic stewardship; urinary tract infection; dog; cat; local sensitivity
1. Introduction
The antimicrobial resistance (AMR) phenomenon is well known, and several control
strategies are currently used worldwide, both for human and veterinary medicine [1].
Among all of these procedures, the antibiotic stewardship program (ASP) in small animal
clinical practices is becoming more and more important [2,3]. This approach is focused on
reducing inappropriate antimicrobial prescription, which is usually caused at the beginning
of empiric treatment without an appropriate diagnostic procedure. This does not allow for
the identification of the etiology of a pathology [3].
Urinary tract infections (UTIs) are among the most commonly diagnosed diseases
in companion animals, which prematurely receive an empirical antibiotic treatment, fre-
quently without confirmation by microbiological exam [4].
The extreme variability in antimicrobial resistance diffusion all over the world, espe-
cially considering multidrug-resistant (MDR) bacteria, is well described and underlines the
importance of developing specific local antibiotic surveillance programs and prescribing
guidelines [5,6].
Targeted therapy is a good tool to limit the spread of resistance in clinics and hospitals.
It was previously reported that resistant bacteria can be transmitted from patient to patient
through contact with medical and nursing staff to healthy animal carriers, and they can
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be maintained on surfaces [2]. These aspects are important from a public health point of
view and could lead to the longer hospitalization of the patient, increased demand for
diagnostic tests, and, of course, higher healthcare costs for owners [7]. As the release of
new antimicrobial molecules in the next few years is possible, it is important firstly to
consider that it is unlikely and, even if this does happen, people will be prioritized with
the available drugs [8]. Moreover, European legislation will be increasingly stringent with
respect to the use of antimicrobials in veterinary medicine [9]. Therefore, the use of these
drugs will respect the well-established concept of rational and prudent use, and it will
be necessary to justify their use through laboratory tests with the final aim to increase a
tailored approach to the patients and their pathology. Several authors extensively explained
the reasons for their concerns regarding the spread of antibiotic resistance. Therefore, many
articles were written using a retrospective approach: A plethora of variables were taken
into consideration to evaluate how this phenomenon can be limited [2,10]. Microbiological
culture and antimicrobial susceptibility tests are considered the gold standard methods to
achieve a correct diagnosis and to reach an individualized treatment based on a decision-
making process [11–13].
It is known that the higher resistance frequency found in cases of UTIs in Southern
European countries compared to Northern European countries is due to less severe regula-
tions and poor surveillance programs for antibiotic prescription in companion animals [10].
According to all aforementioned factors, an improvement in surveillance and more con-
scious antibiotic prescription are required to reduce the AMR phenomenon in Southern
European countries, such as Italy. Moreover, it was previously well established that clinical
data have to be collected and must be correlated to clinical situations, as retrospective
reports lack clinical correlation [6,10]
Veterinary medicine in which ASPs are still largely underdeveloped is a complex issue,
and considering the important statements obtained by previous papers, the aim of the
present study was to propose a specifically designed decision-to-make protocol to treat
urinary tract infections in dogs and cats, with the final goal to prescribe antibiotics only in
cases of bacterial isolation and with the specific indication of a susceptibility test, avoiding
empirical treatment. Moreover, patients were monitored according to a control visit plan to
elucidate if the treatment permitted them to find a clinical and microbiological cure and, if
the therapeutic strategy failed, to establish if a reinfection or a recruitment occurred.
2. Results
2.1. Patients
In the present study, 16 dogs and 12 cats were enrolled. All of the patients presented
specific signs and symptoms of a UTI. Among dogs, only one presented recruitment,
while two dogs were euthanized within one month after the first visit due to the critical
conditions caused by concomitant diseases (both were terminal cancer patients). None of
them received empirical antibiotic treatment, and it was possible to schedule a complete
follow-up according to the control visit plan. Among cats, none died, but it was not possible
to follow up with one patient, due to of the owner’s decision to change veterinarians.
Only one patient, in accordance with the planned rescue therapy, received an empirical
treatment with amoxicillin and clavulanic acid, due to the serious clinical condition and the
concomitance of other diseases: No bacteria were isolated, and the therapy was interrupted
five days from the beginning of treatment. According to previous considerations, 14 dogs
and 11 cats were considered for follow-up visits.
2.2. Susceptibility Tests
All samples were sent immediately to the laboratory and deemed adequate for carry-
ing out the culture. No mixed infections were detected. Escherichia coli (E. coli) was isolated
in most of the canine samples (8/14), followed by Proteus mirabilis (2/4) and Streptococcus
canis (2/14), while E. coli (3/11), Staphylococcus pseudintermedius (3/11), and Staphylococcus
aureus (2/11) were mainly identified among feline samples (Figure 1).
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Figure 1. The figure represents the distribution of the different bacteria isolated in canine (n = 14) and feline (n = 11) urine
samples collected by cystocentesis in patients presenting acute signs of urinary tract infection.
Considering the global distribution of the results obtained by the susceptibility test in
canine urine samples, the highest percentage of resistance (more than 30%) was demon-
strated for ampicillin, cephalexin, cephalothin, enr floxacin, marbofloxaci , doxycycline,
and tetracycline (Figur 2).
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Figure 2. Figure represents sensitivity (S), intermediate (I), or resistance (R) to different antimicrobial drugs tested in
susceptibility test, according to minimal inhibitory concentration (MIC) values considered by CLSI guidelines [11].
Among feline urine samples, the highest resistances (more than 30%) were highlighted
for ampicillin, amoxicillin, clavulanic acid, benzylpenicillin, cephalexin, cephalothin, ce-
fovecin, ceftiofur, clindamycin, enrofloxacin, marbofloxacin, pradofloxacin, doxycycline,
tetracycline, and trimethoprim/sulfamethoxazole (Figure 3).
Susceptibility tests also reported on the cefoxitin screen, which is a phenotypic indi-
cation of methicillin resistance, mainly caused by the presence of mecA and mecC genes.
Moreover, the susceptibility to oxacillin was also tested: All the isolated Staphylococci were
positive to the cefoxitin screen and resistant to oxacillin, indicating that they were methicillin-
resistant Staphylococcus aureus (MRSA) and Staphylococcus pseudintermedius (MRSP).
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Figure 3. Figure represents sensitivity (S), intermediate (I), or resistance (R) to different antimicrobial drugs tested in
susceptibility test, according to minimal inhibitory concentration (MIC) values considered by CLSI guidelines [11].
More specifically, only the most prevalent isolated bacteria for both species were
considered: Bacteria isolated only in one sample were not considered for further comments.
The percentages of sensitivity and resistance obtained by canine and feline samples are
presented in Tables 1 and 2, respectively.
Table 1. Table summarizes most representative bacteria isolated from urine samples in dogs (n = 14). Legend: S = sensitive,
I = intermediate, R = resistant. Bacteria were ranked according to minimal inhibitory concentration (MIC) values presented
in CLSI guidelines [11].
Drug E. coli (8/14) Proteus mirabilis (2/14) Str ptococcus canis (2/14)
S (%) I (%) R (%) S (%) I (%) R (%) S (%) I (%) R (%)
Ampicillin 50 - 50 - - - - - -
Amoxicillin - - - - - - 100 - -
Amoxicillin/
clavulanic acid 62.5 - 37.5 100 - - - - -
Benzylpenicillin - - - - - - 100 - -
Cephalexin - - 100 - 50 50 100 - -
Cephalothin 12.5 12.5 75 50 50 - 100 - -
Cefpodoxime 100 - - 100 - - 100 - -
Cefovecin 100 - - 50 50 - 100 - -
Ceftiofur 100 - - - - 100 - - 100
Cefotaxime - - - - - - 100 - -
Ceftriaxone - - - - - - 100 - -
Imipenem 100 - - - - - - - -
Eritromycin - - - - - 100 100 - -
Amikacin 100 - - 100 - - - - -
Gentamycin 75 - 25 100 - - - - -
Neomicyn 75 - 25 50 50 - 50 50 -
Enrofloxacin 75 - 25 50 - 50 50 50 -
Marbofloxacin 75 - 25 50 - 50 100 - -
Pradofloxacin 75 - 25 - - 100 50 - 50
Doxyciclyne 75 - 25 - - 100 100 - -
Tetracycline 75 - 25 - - 100 - - 100
Nitrofurantoin 50 50 - - - 100 - - -
Chloramphenicol 25 50 25 100 - - - - -
Trimethoprim/
Sulfamethoxazole 75 - 25 100 - - 100 - -
ESBL neg Not evaluated Not evaluated
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Table 2. Table summarizes most representative bacteria isolated from urine samples in cats (n = 11). Legend: S = sensitive,
I = intermediate, R = resistant. Bacteria were ranked according to minimal inhibitory concentration (MIC) values presented
in CLSI guidelines [11].
Drug E. coli (3/11) Staphylococcus pseudintermedius (3/11) Staphylococcus aureus (2/11)
S (%) I (%) R (%) S (%) I (%) R (%) S (%) I (%) R (%)
Ampicillin 100 - - - - 100 - - 100
Amoxicillin/
clavulanic acid 100 - - - - 100 - - 100
Oxacillin - - 100 - - 100 - - 100
Benzylpenicillin - - 100 - - 100 - - 100
Cephalexin - - 100 - - 100 - - 100
Cephalothin - 66 34 - - 100 - - 100
Cefpodoxime 100 - - - - - - - -
Cefovecin 100 - - - - 100 - - 100
Ceftiofur 100 - - - - 100 - - 100
Imipenem 100 - - - - - - - -
Eritromycin - - - - - 100 100 - -
Clindamycin - - - - - 100 50 - 50
Amikacin 100 - - - - - - - -
Gentamycin 100 - - - 34 66 100 - -
Kanamicin - - - - - 100 100 - -
Neomicyn 100 - - - 34 66 100 - -
Enrofloxacin 100 - - - - 100 50 - 50
Marbofloxacin 100 - - - - 100 50 - 50




- - - neg neg
Doxyciclyne 100 - - - - 100 50 - 50
Tetracycline 100 - - - - 100 50 - 50
Nitrofurantoin 100 - - 100 - - 100 - -
Chloramphenicol 100 - - 66 - 34 100 - -
Trimethoprim/
Sulfamethoxazole 100 - - - - 100 100 - -
ESBL neg Not evaluated Not evaluated
Cefoxitin screen Not evaluated pos pos
2.3. Antibiotic Treatment
After receiving the results, a decision regarding therapy was made according to the
susceptibility test, checking the lowest minimal inhibitory concentration (MIC) value.
According to this, among dogs, beta-lactams (6/14), fluoroquinolones (6/14), gentamicin
(1/14), and tetracycline (1/14) were prescribed. Among cats, the therapy was set with
beta-lactams (6/11), fluoroquinolones (3/11), clindamycin (1/11), and nitrofurans (1/11).
Antibiotic treatments are summarized in Tables 3 and 4, for dogs and cats, respectively.
Table 3. Table summarizes drugs used to treat dogs according to results of susceptibility test, frequency of the different
treatments considering total number of enrolled dogs (14), bacteria isolated in urine samples, clinical and the microbiological
outcomes considering number of dogs that received that specific therapy.
Therapy Frequency (n = 14) Bacteria
Outcomes
Clinical Cure Microbiological Cure






Beta lactams 6/14 Enterococcus faecalis, E. coli Yes(6/6)
Yes
(6/6)
Doxycycline 1/14 Klebsiella Pneumoniae Yes Yes (1/1)
Gentamicin 1/14 Proteus mirabilis Yes Yes (1/1)
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Table 4. Table summarizes drugs used to treat cats according to results of susceptibility test, frequency of different treatments
considering total number of enrolled cats (11), bacteria isolated in urine samples, clinical and microbiological outcomes
considering number of cats that received that specific therapy.
Therapy Frequency (n = 11) Bacteria
Outcomes
Clinical Cure Microbiological Cure
Beta lactams 6/11 Corynebacterium aurimucosum, E. coli,Staphylococcus aureus Yes (6/6) Yes (6/6)
Fluoroquinolones 3/11 Staphylococcus pseudointermedius,Enterococcus faecalis Yes (3/3) Yes (3/3)
Nitrofuratoin 1/11 Staphylococcus pseudointermedius, Yes (1/1) Yes (1/1)
Clindamicycin 1/11 Staphylococcus aureus Yes (1/1) Yes (1/1)
2.4. Patient Outcomes
The follow-up visits for the 14 dogs and the 11 cats in the present study were checked
according to the scheduled control visit plan. None demonstrated side effects. All owners
agreed with the control visit plan and demonstrated compliance with veterinarians and
with the protocol. All of the patients were visited weekly and demonstrated an improve-
ment in clinical conditions, with a reduction in the number of signs and symptoms of
a UTI. The microbiological isolation and the susceptibility test were performed for each
patient, and 13 out of 14 dogs and all the cats demonstrated etiological healing associated
with a clinical improvement. Only 1 dog out of 14 was considered for recruitment since
Streptococcus canis was still identified at a concentration of more than 1000 cfu/mL, even if
the patient did not present symptoms of a UTI. The clinical and microbiological outcomes
are summarized in Tables 3 and 4 for dogs and cats, respectively.
3. Discussion
Establishing a rational working flow and prescribing antibiotic treatment only after
receiving the antibiotic susceptibility test results seem to be a good way to treat the patient
specifically and avoid recruitment. This important statement is in accordance with another
recent paper, which underlined the importance of a well-designed working flow to cir-
cumscribe patient information and to choose the right antibiotic treatment consciously [3].
In the last few years, some papers were published on ASP in several countries all over
the world, and guidelines were released to be adopted as national requirements and for
local needs [6,14,15]. Our approach allows for the integration of international guidelines
and an understanding of the level of local sensitivity involved in recording a resistance
surveillance report and to prescribe a tailored therapy.
Considering the most prevalent bacteria isolated in the present study, only E. coli,
Proteus mirabilis, and Streptococcus canis for dogs and E. coli, Staphylococcus aureus, and
Staphiloccocus pseudintermedius for cats were considered for the discussion. In contrast
with another paper [5], we considered not only MIC, but also the extended spectrum
beta-lactamase (ESBL) profile cefoxitin screen and oxacillin test. All of the isolated E. coli
were negative for ESBL and demonstrated 75% resistance against cephalothin in dogs and
66% intermediate resistance in cats. Proteus mirabilis in dogs demonstrated an increased rate
of resistance against cephalosporins, imipenem, and neomycin. Streptococcus canis demon-
strated 50% resistance against neomycin only. Staphylococcus aureus and pseudintermedius
isolated in cat samples were all positive to the cefoxitin screen and resistant to oxacillin.
According to this, they were all classified as MRSA and MRSP and were absolutely resistant
to beta lactams. Staphylococcus pseudintermedius were totally resistant to fluoroquinolones,
tetracyclines, clindamycin, and kanamycin and were partially resistant to chloramphenicol
and neomycin. Staphylococcus aureus was partially resistant to tetracycline.
Multidrug resistance was previously defined as non-intrinsic resistance to three or
more of the antimicrobial categories, but methicillin-resistant staphylococci are consid-
ered MRD, even if they are susceptible to other categories of antibiotics. According to
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this statement, not one of the bacteria isolated in the present study could be considered
MDR [5,16].
It could, therefore, be argued that only a few cases were enrolled in the present study.
This is a relative limitation, since only one hospital was considered, and the observational
period lasted for only one year: Other papers reported a multicentric enrollment over a very
long period (up to ten years) [10,11,17]. A previous study by an Italian referral laboratory
enrolled 243 cases in five years, which equates to 48.6 patients per year [10]. We applied
our protocol in a small clinical animal hospital, which is a reference center for emergencies.
Moreover, our study was run during the COVID-19 pandemic, and we continued to enroll
patients in February and March 2020, when Italy became the first European country to face
the pandemic emergency.
In the authors’ opinion, this study boasts multiple strengths.
(i) The study was conceived considering a prospective design: A working flow was
previously established with the entire medical staff in order to pursue antimicrobial
stewardship. The aim was to have an objective approach that was able to limit bias
and to show an example of antimicrobial stewardship that is also achievable and
applicable with small groups of animals while considering a specific pathology, such
as a UTI in this case. The authors agree that further enrollment of patients according
to the present working flow to monitor the progression of AMR is necessary.
(ii) According to sample collection, voluntary voiding was not permitted. It is known that
misinterpretation due to contaminated bacteria occurs; thus, the collection method
might affect the quantity and the quality of isolates [6,17–19].
(iii) Samples were delivered in few hours and arrived in the laboratory in 24 h at controlled
temperature conditions: This is a milestone that avoids both false positive and false
negative cultures due to delayed deliveries [6,20].
(iv) Contrary to other studies [14,21], it was decided a priori not to begin an empiric
treatment as routine practice but to prescribe the treatment only at the end of the
working flow. This could allow for a reduction in the amount of bias linked to in-
house testing, a high operator-dependent variability and, to limit risk, avoiding an
attitude that is common in some cases [3]. Bacterial culture could be a good tool
in decisional processes which obviously entail withholding antibiotic therapy: This
condition could be acceptable if the results of culture testing are available within a
short period, if no life-threatening conditions or severe clinical signs occur, and if
detrimental effects on outcomes are not induced [6].
(v) The workflow was decided by medical staff with the compliance of the entire clinical
staff: This approach enhances the common ownership of the ASP. This aspect was
underlined by Guardabassi and Prescott [2], who also explained the importance of
having an “ASP team”. We tried to establish a similar protocol, defining internal
responses to infectious disease, in connection with specialists in veterinary pharma-
cology and with a laboratory capable of carefully and quickly processing the samples.
The ASP team should be able to write specific guidelines, according to national and
international regulations, dividing drugs with specific pharmacokinetic and pharma-
codynamic information that are related to the different pathologies. These guidelines
should be revised and updated every year and tailored to specific contexts [2,14,22].
(vi) In our study, we evaluated the clinical outcomes of all enrolled patients. This as-
pect, in our opinion, gives strength to our ASP, and it is in line with what is pro-
posed by other authors [6,10] and differs from recent papers [5,11,21], which did not
record any information about patient follow-up. We think that this is important as a
means of completing the general picture and to correlate microbiological results with
clinical data.
Since April 2019, Italy adopted a computerized method for drug prescription. This is
an important tool for all veterinarians, as the integrated handbook can provide suggestions
(e.g., posology or, considering food-producing animals, withdrawal period). Moreover,
this system can suggest outcomes of the prescription and consumption of antimicrobial
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drugs, divided by species, pathology, apparatus, and type of drugs. The papers of Lehner
et al. [23] and Hubbuc et al. [15] demonstrated that, in Switzerland, the introduction of
the online antimicrobial stewardship program, which gives advice/recommendations,
significantly decreased the prescription of antimicrobials for UTIs in dogs and cats. In the
complex context of ASP, this kind of tool could be enrolled among “educational” tools.
Moreover, monitoring the national attitude for prescribing drugs is a useful tool.
It was previously widely described that traditional antimicrobial treatment increased
resistance phenomena in the bacteria responsible for UTIs in dogs and cats [10]. It is quite
commonly reported that dogs and cats presenting signs of lower UTIs, and referred to
first-line opinion veterinarians, received empirical treatment with antimicrobial drugs,
even if these signs were not caused by bacterial infection [5,14]. Laboratory tests, such
as microscopy, culture, and antimicrobial susceptibility tests, are usually performed in
the case of relapse after a first empirical therapeutical attempt [4,24]. It is possible to find
in the literature papers corroborating that it is possible to start empirical treatment with
trimethoprim and sulfamethoxazole or amoxicillin in patients with UTIs due to the fact that
80% of cases still demonstrate susceptibility to these drugs [5,14]. It was also reported that
29% of dogs empirically treated for UTIs required a variation of pharmacological strategy,
mainly due to re-evaluation after obtaining susceptibility test results [3]. According to this
information, it is important to evaluate the application of empirical treatment carefully
because a high percentage of cases is not sensitive to this therapy, or it could indue selective
pressure, leading to and increasing resistance. In 2017, Rampacci and colleagues [11]
considered, in a retrospectively designed study, the impact of empirical treatment in canine
and feline UTIs in Italy. According to their results, the empirical treatment should not be
started prior to receiving of the microbiological assay results due to the high risk to select
resistant bacteria that are potentially dangerous for humans and animals. However, they
did record patient outcomes and underlined the importance of developing appropriate
therapeutic protocols. The data obtained by Rampacci and co-workers are partially in
agreement with those recorded in our study, considering that E. coli was the most prevalent
microorganism in dogs. That being said, we demonstrated that Staphylococcus aureus and
pseudintermedius have a high prevalence in cats.
The high percentage of antimicrobial resistance for certain molecules observed in the
present study could be explained by the fact that the hospital where patients were enrolled
is a referral center for more complex or urgent clinical cases. Consequently, patients came
from other small practices where improper drug use or empirical treatment might happen.
This variable was previously reported on by other authors [11,19].
An improvement to our working-flow will be to reduce or avoid the prescription of
drugs belonging to the upper classes of the Antimicrobial Advice Ad Hoc Expert Group
(AMEG) classification, or those encoded in the critically important antimicrobials (CIAs)
list [1,9]. In the present study, according to laboratory reports and clinical conditions, fluoro-
quinolones were prescribed. In the future, we aim to improve the prescription of nitrofuran,
such as nitrofurantoin, which was demonstrated to have a very low percentage of resistance
in the samples analyzed for the present paper, which could be effective against a wider
group of the pathogens responsible for UTIs (E. coli, Klebsiella, Enterobacter, Enterococci,
Staphylococcus aureus and epidermidis, Salmonella, Shigella, and Corynebacterium) [25,26].
4. Materials and Methods
4.1. Study Design
The study was designed as a prospective single-center observational study in a small
animal hospital in Northwest Italy. The working flow was inspired by previously published
methods [27,28] with slight modifications to enroll only patients presenting acute UTI signs
and to consider both dogs and cats. The definitive working flow adopted in the present
study is presented in Figure 4.
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Informed consent was obtained from all owners, who gave permission to use the
collected data and clinical information.
4.2. Data Collection
Animals were recruited from January to December 2020. On the day of consultation,
patient signalment, clinical history, all clinical and diagnostic procedures, and previous
pharmacological treatments were recorded.
4.3. Study Population
Dogs and cats of any breed, sex, and age, and presenting specific clinical signs of
UTIs (stranguria, pollakiuria, hematuria) associated with indirect signs (licking, anorexia,
depression) were enrolled.
4.4. Urine Samples nd Microbiological Assays
All uri e sampl s wer collected by cystocentesis in sterile silicone-coated tubes
and were sent to the laboratory to perform bacteria isolation and antibiotic-susceptibility
tests, according to the Clinical & Laboratory Standards Institute (CLSI) guidelines (VET08,
2018) [24,29]. A cut-off value of more than 1000 colony forming units (CFU)/mL was
considered to be clinically significant.
4.5. Antibiotic Treatment
Antibiotic treatment prior to receiving the antibiotic susceptibility test results as
avoided, but rescue therapy using amoxicillin and clavulanic acid in the case of life-
threatening conditions was permitted while waiting for the results. After receiving the
results, antibiotic treatment was chosen, according to the MIC value. The prescription was
written using the electronic method and respecting the posology, without changes.
4.6. Outcomes
A follow-up of all patients was scheduled, according to a control visit plan that en-
compassed a clinical check one week after the beginning of the therapy and a susceptibility
test three weeks after the last day of drug administration. During the visits, general health
status, monitoring of the correct drug administration, and the collection of information by
the owners were recorded. These data were used to evaluate clinical and microbiological
cures, and to assess the effectiveness of all antimicrobial treatments [30].
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4.7. Data Management and Statistical Analysis
Data were organized using Excel software (Microsoft, Redmond, WA, USA), and
descriptive statistics were performed using Prism 9.0 software (GraphPad, San Diego,
CA, USA).
5. Conclusions
Several papers dealt with the problem of antimicrobial resistance in veterinary medicine
using a retrospective approach. Most of them demonstrated the necessity of improving
clinical practice to obtain a tailored antibiotic treatment. Considering these studies, we
tried to propose a new working flow that is easy to reproduce and to explain to owners.
Our experience was positive and allowed for a rational approach and a high success rate,
limiting prescription and the use of empirical treatment. These findings underline the
contribution of veterinary medicine on the management of antimicrobial resistance and the
need for veterinarians to prescribe and use antimicrobial drugs in a careful way, without
impacting animal welfare. To do so, antimicrobials should be prescribed and used only if
necessary, choosing the appropriate molecule for the causative strain.
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